159 related articles for article (PubMed ID: 25918110)
1. Determination of the protein expression profiles of breast cancer cell lines by quantitative proteomics using iTRAQ labelling and tandem mass spectrometry.
Calderón-González KG; Valero Rustarazo ML; Labra-Barrios ML; Bazán-Méndez CI; Tavera-Tapia A; Herrera-Aguirre ME; Sánchez del Pino MM; Gallegos-Pérez JL; González-Márquez H; Hernández-Hernández JM; León-Ávila G; Rodríguez-Cuevas S; Guisa-Hohenstein F; Luna-Arias JP
J Proteomics; 2015 Jun; 124():50-78. PubMed ID: 25918110
[TBL] [Abstract][Full Text] [Related]
2. Data set of the protein expression profiles of Luminal A, Claudin-low and overexpressing HER2(+) breast cancer cell lines by iTRAQ labelling and tandem mass spectrometry.
Calderón-González KG; Valero Rustarazo ML; Labra-Barrios ML; Bazán-Méndez CI; Tavera-Tapia A; Herrera-Aguirre Ma; Sánchez Del Pino MM; Gallegos-Pérez JL; González-Márquez H; Hernández-Hernández JM; León-Ávila G; Rodríguez-Cuevas S; Guisa-Hohenstein F; Luna-Arias JP
Data Brief; 2015 Sep; 4():292-301. PubMed ID: 26217805
[TBL] [Abstract][Full Text] [Related]
3. Comparative proteomic analysis of different stages of breast cancer tissues using ultra high performance liquid chromatography tandem mass spectrometer.
Al-Wajeeh AS; Salhimi SM; Al-Mansoub MA; Khalid IA; Harvey TM; Latiff A; Ismail MN
PLoS One; 2020; 15(1):e0227404. PubMed ID: 31945087
[TBL] [Abstract][Full Text] [Related]
4. Comparison of functional proteomic analyses of human breast cancer cell lines T47D and MCF7.
Aka JA; Lin SX
PLoS One; 2012; 7(2):e31532. PubMed ID: 22384035
[TBL] [Abstract][Full Text] [Related]
5. Mass spectrometric characterization of protein structure details refines the proteome signature for invasive ductal breast carcinoma.
Röwer C; Koy C; Hecker M; Reimer T; Gerber B; Thiesen HJ; Glocker MO
J Am Soc Mass Spectrom; 2011 Mar; 22(3):440-56. PubMed ID: 21472563
[TBL] [Abstract][Full Text] [Related]
6. Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome?
Smith L; Qutob O; Watson MB; Beavis AW; Potts D; Welham KJ; Garimella V; Lind MJ; Drew PJ; Cawkwell L
Neoplasia; 2009 Nov; 11(11):1194-207. PubMed ID: 19881955
[TBL] [Abstract][Full Text] [Related]
7. High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers.
Terkelsen T; Pernemalm M; Gromov P; Børresen-Dale AL; Krogh A; Haakensen VD; Lethiö J; Papaleo E; Gromova I
Mol Oncol; 2021 Feb; 15(2):429-461. PubMed ID: 33176066
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
[TBL] [Abstract][Full Text] [Related]
9. Combined Proteomics and Transcriptomics Identifies Carboxypeptidase B1 and Nuclear Factor κB (NF-κB) Associated Proteins as Putative Biomarkers of Metastasis in Low Grade Breast Cancer.
Bouchal P; Dvořáková M; Roumeliotis T; Bortlíček Z; Ihnatová I; Procházková I; Ho JT; Maryáš J; Imrichová H; Budinská E; Vyzula R; Garbis SD; Vojtěšek B; Nenutil R
Mol Cell Proteomics; 2015 Jul; 14(7):1814-30. PubMed ID: 25903579
[TBL] [Abstract][Full Text] [Related]
10. Multipronged quantitative proteomics reveals serum proteome alterations in breast cancer intrinsic subtypes.
Gajbhiye A; Dabhi R; Taunk K; Jagadeeshaprasad MG; RoyChoudhury S; Mane A; Bayatigeri S; Chaudhury K; Santra MK; Rapole S
J Proteomics; 2017 Jun; 163():1-13. PubMed ID: 28495502
[TBL] [Abstract][Full Text] [Related]
11. An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma.
Mangé A; Dimitrakopoulos L; Soosaipillai A; Coopman P; Diamandis EP; Solassol J
J Proteomics; 2016 Jun; 142():114-21. PubMed ID: 27168011
[TBL] [Abstract][Full Text] [Related]
12. Proteomics pipeline for biomarker discovery of laser capture microdissected breast cancer tissue.
Liu NQ; Braakman RB; Stingl C; Luider TM; Martens JW; Foekens JA; Umar A
J Mammary Gland Biol Neoplasia; 2012 Jun; 17(2):155-64. PubMed ID: 22644111
[TBL] [Abstract][Full Text] [Related]
13. Protein Corona Gold Nanoparticles Fingerprinting Reveals a Profile of Blood Coagulation Proteins in the Serum of HER2-Overexpressing Breast Cancer Patients.
Chantada-Vázquez MDP; Castro López A; García-Vence M; Acea-Nebril B; Bravo SB; Núñez C
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182810
[TBL] [Abstract][Full Text] [Related]
14. Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique.
Huang Y; Zhang X; Jiang W; Wang Y; Jin H; Liu X; Xu C
Eur J Obstet Gynecol Reprod Biol; 2012 Nov; 165(1):96-103. PubMed ID: 22818854
[TBL] [Abstract][Full Text] [Related]
15. iTRAQ-based proteomic profiling of breast cancer cell response to doxorubicin and TRAIL.
Leong S; Nunez AC; Lin MZ; Crossett B; Christopherson RI; Baxter RC
J Proteome Res; 2012 Jul; 11(7):3561-72. PubMed ID: 22587632
[TBL] [Abstract][Full Text] [Related]
16. Comparative membrane proteomics analyses of breast cancer cell lines to understand the molecular mechanism of breast cancer brain metastasis.
Peng W; Zhang Y; Zhu R; Mechref Y
Electrophoresis; 2017 Sep; 38(17):2124-2134. PubMed ID: 28523741
[TBL] [Abstract][Full Text] [Related]
17. Mass spectrometry (LC-MS/MS) identified proteomic biosignatures of breast cancer in proximal fluid.
Whelan SA; He J; Lu M; Souda P; Saxton RE; Faull KF; Whitelegge JP; Chang HR
J Proteome Res; 2012 Oct; 11(10):5034-45. PubMed ID: 22934887
[TBL] [Abstract][Full Text] [Related]
18. Glycoproteins in Claudin-Low Breast Cancer Cell Lines Have a Unique Expression Profile.
Yen TY; Bowen S; Yen R; Piryatinska A; Macher BA; Timpe LC
J Proteome Res; 2017 Apr; 16(4):1391-1400. PubMed ID: 28287265
[TBL] [Abstract][Full Text] [Related]
19. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry.
Ralhan R; Desouza LV; Matta A; Tripathi SC; Ghanny S; Datta Gupta S; Bahadur S; Siu KW
Mol Cell Proteomics; 2008 Jun; 7(6):1162-73. PubMed ID: 18339795
[TBL] [Abstract][Full Text] [Related]
20. Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics.
Nagaraja GM; Othman M; Fox BP; Alsaber R; Pellegrino CM; Zeng Y; Khanna R; Tamburini P; Swaroop A; Kandpal RP
Oncogene; 2006 Apr; 25(16):2328-38. PubMed ID: 16314837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
